Drug Profile
AZD 9819
Alternative Names: AZD9819Latest Information Update: 01 Aug 2011
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiasthmatics
- Mechanism of Action Leucocyte elastase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 31 Aug 2010 Phase-I clinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)